Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Eyes IO Growth With BeiGene China Pact

Executive Summary

Celgene splashes $150m to buy a stake in BeiGene of China and $263m upfront to get rights to a PD-1 antibody that could catapult the US firmly up the immuno-oncology ladder.

Advertisement

Related Content

Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer
Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases
Scrip Asks… What's The Current Climate For Deal-Making? (Part 1)
Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
Celgene Eases Angst Over Otezla, Sets The Stage For Growth
Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard (Part 2)
Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard
Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea
FDA Clinical Hold Hits Keytruda Multiple Myeloma Studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel